Canadian particle accelerator center TRIUMF has entered a collaboration with Fusion Pharmaceuticals for the production of actinium-225, which has potential as a cancer-killing radioisotope.
Under the deal, Fusion will provide a financial investment that will enable TRIUMF to upgrade its production infrastructure for actinium-225. In return, Fusion will gain preferred access to actinium-225, an alpha-emitting isotope with a short half-life that can be combined with a molecular agent to target cancer cells.
Fusion is developing a line of targeted alpha therapies based on actinium-225 for radiation therapy applications.
